FDA Updates Investigation on Valsartan Impurities, Expands Recall

FDA Commissioner Scott Gottlieb announced more recalls Thursday in the FDA’s ongoing investigation into contaminated valsartan products and said the impurity may be a byproduct of the API manufacturing process.
Source: Drug Industry Daily